Previous Close | 6.40 |
Open | 6.40 |
Bid | 6.10 |
Ask | 7.20 |
Strike | 12.50 |
Expire Date | 2024-06-21 |
Day's Range | 6.40 - 6.40 |
Contract Range | N/A |
Volume | |
Open Interest | 91 |
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.